A recent study reveals that patients who come off blockbuster GLP-1 drugs like semaglutide or tirzepatide may regain lost weight at a significantly accelerated pace than those who end traditional diet and exercise programs.
Findings released in a major medical journal points out that while overweight people often shed about a fifth of their body weight while undergoing treatment, the weight is regained at an average rate of 0.8 kg per month upon discontinuation.
"People purchasing these medications need to be cognizant of the risk of rapid rebound weight gain when the medication ends," stated expert Dr. Susan Jebb.
This pace of regain means a reversion to pre-treatment mass in about a year and a half.
Weighing Treatments
The study, which examined dozens of trials involving thousands of patients, compared the outcomes of the injectable medications with conventional dieting.
Researchers point out that people who lose weight through dieting generally have a slower creep back—approximately 100 grams monthly—post-intervention.
Understanding the Quick Regain
Nutrition scientists propose the mechanism of the jabs explains the amplified regain.
These medications mimic a natural hormone called glucagon-like peptide-1, which controls hunger.
"Artificially providing GLP-1 levels far above than the body's typical production may cause the body to generate a reduced amount of its endogenous GLP-1, and could diminish responsiveness to its actions," noted Dr. Adam Collins, a dietetics expert.
"Discontinuation of this hormone supplement means hunger is no longer kept in check, making binge eating a significant risk."
A Chronic Disease?
The NHS advise the injections for people with obesity-related medical conditions, accompanied by recommended diet and exercise modifications.
Many experts argue that, due to the significant potential of weight regain, the treatment is often ongoing.
This view is echoed by pharmaceutical companies, who say that the results "underscore the chronic character of obesity," comparing it to managing diseases like high blood pressure.
User Accounts
Users who have stopped the medication explain a intense resurgence of hunger.
"I experienced something flipping and I was suddenly extremely hungry," recalled an individual.
The struggle is exacerbated if users have not established permanent dietary or behavioural modifications during treatment.
Growing Interest
Recent estimates indicate that a significant number of people in the UK have used these injections in the last 12 months, with interest being substantial.
- Use is greater among women than males.
- The 40s and 50s age group shows the greatest usage rates.
- A large proportion access the drugs through private healthcare rather than the NHS.
Finally, experts caution that while GLP-1 drugs are potent agents for weight loss, they are not a magic cure and lasting health benefits relies on combined lifestyle changes.
